Polymalic acid-based multifunctional drug delivery system

1. A drug delivery system comprising: a polymerized polymalic acid molecular scaffold having a plurality of pendant carboxylic acid groups; a plurality of biologically active molecular modules, wherein each module is covalently linked to a pendant carboxylic acid of the polymerized polymalic acid molecular scaffold, wherein the biologically active molecular modules comprise: at least one targeting antibody for promoting cellular uptake by a target cell; and at least one pro-drug for altering cellular metabolism of the target cell, wherein the at least one pro-drug includes a pro-drug that alters expression of protein kinase CK2 and the at least one targeting antibody binds to bradykinin receptors, or an EGF receptor.

2. The drug delivery system according to claim 1 , wherein the pro-drug inhibits or substantially reduces expression of protein kinase CK2.

3. The drug delivery system according to claim 1 , wherein the polymerized polymalic acid molecular scaffold comprises at least one molecule selected from: poly(β-L-malic acid), poly(β-D-malic acid), poly(β-D,L-malic acid), poly(α-L-malic acid), poly(α-D-malic acid), poly(α-D,L-malic acid) and poly(α,β-D,L-malic acid).

4. The drug delivery system according to claim 3 , wherein the poly(β-L-malic acid) has a molecular mass between 2,500 and 100,000.

5. The drug delivery system according to claim 4 , wherein the poly(β-L-malic acid) has a molecular mass of at least about 5,000.

6. The drug delivery system according to claim 1 , wherein each molecule of the polymerized polymalic acid molecular scaffold has at least about 50 pendant carboxylic acid groups.

7. The drug delivery system according to claim 1 , wherein the plurality of molecular modules further includes a molecular module for promoting disruption of biomembranes.

8. The drug delivery system according to claim 7 , wherein the molecular module for promoting disruption of biomembranes comprises a molecule having lipophilic characteristics and groups that are charged at physiologic pH and become uncharged at lysosomal pH thereby increasing lipophilicity of said molecular module.

9. The drug delivery system according to claim 1 , wherein the plurality of active molecular modules further includes a molecular module for prolonging circulation of the drug delivery system.

10. The drug delivery system according to claim 9 , wherein the molecular module for prolonging circulation of the drug delivery system comprises polyethylene glycol.

11. The drug delivery system according to claim 1 , wherein the plurality of biologically active molecular modules further includes a reporter module for determining cellular and tissue uptake of the drug delivery system.

12. The drug delivery system according to claim 11 , wherein the reporter module comprises a fluorescent molecule.

13. The drug delivery system according to claim 1 , wherein the targeting antibody is selected to promote penetration of the blood brain barrier.

14. The drug delivery system according to claim 1 , wherein the antibody is a monoclonal antibody.

15. The drug delivery system according to claim 1 , wherein the antibody is a humanized or chimeric antibody.

16. The drug delivery system according to claim 1 , wherein the pro-drug is linked to the polymerized polymalic acid molecular scaffold by a cleavable linkage that is cleaved in cytoplasm when the drug delivery system enters a cell.

17. The drug delivery system according to claim 16 , wherein the cleavable linkage is a disulfide linkage.

18. The drug delivery system according to claim 1 , wherein the pro-drug comprises an antisense molecule.

19. The drug delivery system according to claim 18 , wherein the antisense molecule is a morpholino antisense molecule.

20. The drug delivery system according to claim 18 , wherein the antisense molecule interferes with production of a CK2 subunit α.